Cerevel Therapeutics develops pharmacological treatments targeting neurological and neuropsychiatric disorders by investigating deficits in neurocircuitry that contribute to disease symptoms. The company focuses on creating new therapeutic options for patients affected by complex and life-threatening brain diseases, addressing a significant unmet medical need.
Funding
$450M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological and neuropsychiatric disorders present significant challenges due to the complexity of brain circuitry and the resulting deficits that contribute to disease symptoms. Current treatments often fall short of addressing the underlying causes of these conditions, leaving a substantial unmet medical need for patients affected by complex and life-threatening brain diseases.
Solution
Cerevel Therapeutics, now part of AbbVie, focuses on developing novel pharmacological treatments for neurological and neuropsychiatric disorders. The company investigates deficits in neurocircuitry to create therapeutic options that target the root causes of these diseases. By understanding how these deficits drive the development of symptoms, Cerevel aims to deliver meaningful change and improved treatment outcomes for patients.
Target Audience
The primary audience includes patients affected by neurological and neuropsychiatric disorders, as well as healthcare professionals seeking improved treatment options for these conditions.
Features
- Development of therapies targeting neurological disorders
- Focus on neuropsychiatric disorders
- Investigation of deficits in neurocircuitry
- Creation of new treatment options for complex brain diseases